Cardiff Oncology (CRDF) FCF Margin (2011 - 2025)
Cardiff Oncology (CRDF) posted FCF Margin of 2455.56% for Q4 2025, up 72.85% sequentially from 9043.33% in Q3 2025, and up 434378.0% YoY from N/an in Q4 2024.
Cardiff Oncology (CRDF) FCF Margin (2011 - 2025) Analysis & Trends
Cardiff Oncology has reported FCF Margin for 15 years, with the latest figure at 2455.56% in Q4 2025.
- Quarterly FCF Margin rose 434378.0% year-over-year to 2455.56% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 6402.53% (down 88016.0% YoY) and the FY2025 annual result came in at 6402.53%, down 87208.0% from the prior year.
- FCF Margin improved to 2455.56% in Q4 2025 per CRDF's latest filing, from 9043.33% in the prior quarter.
- Over five years, FCF Margin peaked at 2455.56% in Q4 2025 and troughed at 14081.08% in Q1 2022.
- A 5-year average of 7205.62% and a median of 6537.51% in 2021 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2024 and 2025: FCF Margin soared 677814 bps in 2024, then slumped 875050 bps in 2025.
- Over 5 years, FCF Margin stood at 5560.9% in 2021, then declined by 22 bps to 6789.84% in 2022, then soared by 33 bps to 4581.41% in 2023, then plunged by 48 bps to 6799.34% in 2024, then soared by 64 bps to 2455.56% in 2025.
- According to Business Quant data, FCF Margin over the past three periods registered 2455.56%, 9043.33%, and 6158.68% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 70.82% |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2,455.56% |
| Sep 30, 2025 | -9,043.33% |
| Jun 30, 2025 | -6,158.68% |
| Mar 31, 2025 | -12,565.14% |
| Dec 31, 2024 | -6,799.34% |
| Sep 30, 2024 | -6,336.97% |
| Jun 30, 2024 | -5,662.58% |
| Mar 31, 2024 | -3,814.63% |
| Dec 31, 2023 | -4,581.41% |
| Sep 30, 2023 | -5,866.67% |
| Jun 30, 2023 | -6,720.37% |
| Mar 31, 2023 | -10,592.77% |
| Dec 31, 2022 | -6,789.84% |
| Sep 30, 2022 | -8,531.18% |
| Jun 30, 2022 | -7,700.00% |
| Mar 31, 2022 | -14,081.08% |
| Dec 31, 2021 | -5,560.90% |
| Sep 30, 2021 | -6,354.65% |
| Jun 30, 2021 | -6,325.00% |
| Mar 31, 2021 | -8,172.22% |